Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Regeneron Pharmaceuticals, Inc.

NASDAQ: REGN · Life Sciences · 13 alerts · CIK 872589

Share price
$952.40Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Regeneron Pharmaceuticals, Inc. filings on SEC EDGAR ↗

6:56 AM ET 10-Q
Financial Results

Regeneron Pharmaceuticals Q3 2026 Results: Net Income $1.95B, Up 33.5% YoY

Regeneron reported a significant increase in total revenues to $5.12 billion for the third quarter of 2026, driven by strong collaboration revenue and net product sales. Net income for the quarter rose to $1.95 billion, up from $1.46 billion in the prior year period, despite higher research and development expenses.

Key figure
Net income $1.95B · +33.5% YoY
6:51 AM ET 8-K
Financial Results

Regeneron Pharmaceuticals Financial Results

Regeneron reported third quarter 2026 revenues of $5.1 billion, a 36% increase year-over-year, driven by record sales of Dupixent, EYLEA HD, and Libtayo. The company also announced an expanded collaboration with Sanofi involving a $1.0 billion upfront payment and the FDA approval of Pasatru (garetosmab) for fibrodysplasia ossificans progressiva.

Term
Q3 2026

“This was an outstanding quarter for Regeneron, with Dupixent, EYLEA HD, and Libtayo each achieving record net sales. Our pipeline of about 50 product candidates is rapidly advancing. We expect an FDA decision for cemdisiran in generalized myasthenia gravis next month; our Phase 3 programs in multiple myeloma, lymphoma, anticoagulation, and obesity continue to advance; and we have generated encouraging early data in MASH, POTS, and ovarian cancer. Finally, we expanded our alliance with Sanofi to include four Regeneron-invented, next-generation, long-acting antibodies designed to build on the success of Dupixent.”

Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer

“We are pleased with our third quarter financial results, which marked our third consecutive quarter of double-digit growth in both revenue and non-GAAP EPS. Strong commercial execution across our portfolio, together with the anticipated step-up in Sanofi collaboration revenue in the first full quarter following repayment of the Development Balance, drove a 36% increase in total revenues and a 70% increase in non-GAAP EPS, positioning us to deliver one of our strongest years ever.”

Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.